ALUMIS INC. - 8-K Filing
Alumis Inc. reports Q3 2026 net loss of $94.9 million and maintains envudeucitinib NDA submission timeline for 4Q 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ALMS
Read the full article at SEC EDGAR
Part of the story Cibus, Inc. - 8-K Filing (3 articles)